Can prolonged administration of valproic acid put patients with epilepsy at higher risk for development of Alzheimer's disease?

Epilepsy and Behavior

Volumn 12, Issue 1, 2008, Pages 206-207

  Borhani Haghighi, Afshin ^a   Sabayan, Behnam ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; FOLLITROPIN; INSULIN; LUTEINIZING HORMONE; THYROID HORMONE; VALPROIC ACID;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DISEASE DURATION; DISEASE PREDISPOSITION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; EPILEPSY; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HORMONE ACTION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN METABOLISM; INSULIN RESISTANCE; LETTER; LONG TERM CARE; MENSTRUATION DISORDER; MONOTHERAPY; NEUROPATHOLOGY; NEUROPROTECTION; OBESITY; OVARY POLYCYSTIC DISEASE; RISK ASSESSMENT; SIDE EFFECT; WEIGHT GAIN;

ALZHEIMER DISEASE; ANTICONVULSANTS; EPILEPSY; HUMANS; VALPROIC ACID;

EID: 37049024814     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2007.08.014     Document Type: Letter

References (14)

1. Sabayan B., Foroughinia F., and Chohedry A. A postulated role of garlic organosulfur compounds in prevention of valproic acid hepatotoxicity. Med Hypoth 68 (2007) 512-514
2. Verrotti A., Greco R., Latini G., and Chiarelli F. Endocrine and metabolic changes in epileptic patients receiving valproic acid. J Pediatr Endocrinol Metab 18 (2005) 423-430
3. Pylvanen V., Pakarinen A., Knip M., and Isojarvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 8 (2006) 643-648
4. Day C. Metabolic syndrome, or what you will: definitions and epidemiology. Diab Vasc Dis Res 4 (2007) 32-38
5. Zhao W.Q., Chen H., Quon M.J., and Alkon D.L. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 490 (2004) 71-81
6. Plum L., Belgardt B.F., and Bruning J.C. Central insulin action in energy and glucose homeostasis. J Clin Invest 116 (2006) 1761-1766
7. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
8. Carro E., and Torres-Aleman I. The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 490 (2004) 127-133
9. Sabayan B, Foroughinia F, Borhanihaghighi A, Mowla A. Are women with polycystic ovary syndrome (PCOS) at higher risk for development of Alzheimer disease? Alzheimer Dis Assoc Disord 2007;in press.
10. Martin R.C., Griffith H.R., Faught E., Gilliam F., Mackey M., and Vogtle L. Cognitive functioning in community dwelling older adults with chronic partial epilepsy. Epilepsia 2 (2005) 298-303
11. Griffith H.R., Martin R.C., Bambara J.K., Marson D.C., and Faught E. Older adults with epilepsy demonstrate cognitive impairments compared with patients with amnestic mild cognitive impairment. Epilepsy Behav 1 (2006) 161-168
12. Lozsadi D.A., and Larner A.J. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer's disease. Dement Geriatr Cogn Disord 2 (2006) 121-124
13. 18FDG-PET in children with new-onset partial epilepsy: a prospective study. Neurology 5 (2002) 717-722
14. Herrmann N., Lanctot K.L., Rothenburg L.S., and Eryavec G. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord 2 (2007) 116-119